Search for: "Reference Assistant" Results 21 - 40 of 32,895
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
20 Sep 2023, 9:01 pm by renholding
If the EU entity is a parent company, the criteria are assessed by reference to the parent and its EU and non-EU subsidiaries in aggregate. [read post]
20 Sep 2023, 6:00 am by AccelerateEditor
This raises issues of hearsay, which refers to using an out-of-court statement to prove the truth of the matter asserted. [read post]
20 Sep 2023, 5:50 am by Rob Robinson
., the preferred provider of Legal GRC software specifically designed for in-house legal, privacy, and IT teams at Global 2000 and AmLaw 200 organizations, in partnership with the Association for Certified E-Discovery Specialists (ACEDS), the Electronic Discovery Reference Model (EDRM), and eDiscovery Today are pleased to announce the ninth annual celebration of E-Discovery Day will take place on December 7, 2023. [read post]
20 Sep 2023, 2:10 am by Christine Cooper, aequum LLC
Christine leads the firm’s health care practice and is dedicated to assisting and defending plans and patients. [read post]
20 Sep 2023, 2:10 am by Christine Cooper, aequum LLC
Christine leads the firm’s health care practice and is dedicated to assisting and defending plans and patients. [read post]
20 Sep 2023, 12:30 am by John Jenkins
Archives and transcripts will be available on-demand until September 20, 2024, so they’ll be available for you to reference as you navigate challenging proxy season issues well after the live Conferences have concluded. [read post]
19 Sep 2023, 9:30 am by Berry Law
For example, a personal reference, such as a family member, may have keen insight into how living with MST has affected the Veteran’s daily life or well-being. [read post]
19 Sep 2023, 5:20 am by Rob Robinson
Reference:  European Union Agency for Cybersecurity (ENISA) (2023, September 13). [read post]
19 Sep 2023, 3:34 am by Kurt R. Karst
  The FDA Commissioner is quoted as saying that “[t]he FDA stands ready to assist the FTC . . . to help identify and address efforts to block or delay generic drug and biosimilar competition,” but, given FDA’s ministerial role in administering the Orange Book and FDA’s insistence that it will not review patents before they’re listed, it is unclear what FDA role will play. [read post]